At present, efficacy data is primarily derived from the phase I NAVIGATOR clinical trial,7,8 with no evidence from routine clinical practice.10 In response to this lack of data, we conducted a retrospective observational study AVApritinib Real-World Evidence (AVARWE) on a cohort of patients treated with avapritinib that aimed to assess the effectiveness and safety of avapritinib in real-world scenarios involving Spanish patients diagnosed with GIST harboring the D842V-PDGFRA mutation. Here, PDGFRA is linked to gastrointestinal stromal tumor.